搜索
Search
img

News Center

新闻中心

New Start For New Journey! Kintor Relocated To Suzhou R&D Center And Industrialization Base

New Start For New Journey! Kintor Relocated To Suzhou R&D Center And Industrialization Base

(Summary description)On 28 August 2020, Kintor Pharmaceutical Limited (Stock Code: 9939.HK, hereinafter referred to as the “Kintor Pharmaceutical”), officially moved to Suzhou self-established R&D center and industrialization base, symbolising a new development chapter for Kintor Pharmaceutical.

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2020-09-01 11:44
  • Views:
Information

On 28 August 2020, Kintor Pharmaceutical Limited (Stock Code: 9939.HK, hereinafter referred to as the “Kintor Pharmaceutical”), officially moved to Suzhou self-established R&D center and industrialization base, symbolising a new development chapter for Kintor Pharmaceutical.

 

Guests Group Photo of Housewarming Ceremony

 

In the morning of 28 August, Kintor Pharmaceutical held a grand relocation ceremony in the R&D center and industrialization base. Lin Xiaoming, deputy secretary of the Party Working Committee, deputy director of the management committee and head of the organisation department of Suzhou Industrial Park, and other leaders at all levels attended the activity, witnessing the delightful moment together with shareholder representatives, partners and employees of Kintor Pharmaceutical.

 

Suzhou R&D Center and Industrialization Base

 

The self-established Suzhou R&D center and industrialisation base is located at No. 20 Songbei Road, Suzhou Industrial Park, covering an area of approximately 20,000 square meters with a total investment of approximately RMB200 million. Meeting the GMP requirements, the constructed general solid preparation production workshop, external preparation production workshop, QC laboratory, warehouse, animal room, cell, preparation and test laboratory, chemical synthesis laboratory and comprehensive office area are mainly used for self-innovation and R&D of Kintor Pharmaceutical, as well as the production of new drugs such as prochloraz and freitahn. The R&D center and industrialisation base were laid in October 2018. After less than two years of construction, it is officially put into operation today.

 

Office Area in R&D Center

GMP workshop and QC laboratory

 

Dr. Tong Youzhi, founder, chairman and CEO of Kintor Pharmaceutical, said, the completion and putting into operation of Suzhou R&D center and industrialisation base is an important milestone for Kintor Pharmaceutical to step into industrialisation, creating a new journey for the Company’s development. Moving into a new site also provides a better working environment and development platform for employees.

Related documents

There is currently no content to display
Please add data record on website background.